Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
What’s a hallucinogen without the hallucinations? Perhaps a potent and fast-acting antidepressant, according to a new study based on virtual drug screening. → Read More
STAT spoke with Andrew Kaczynski about his family’s journey — and what he believes can be done to help others dealing with pediatric cancer. → Read More
Molecular details of 218 pediatric brain tumors reveals connections between certain proteins and a patient's prognosis. → Read More
Damien Fair, a University of Minnesota neuroscientist, received the honor, but shares a rare and touching research symbiosis with his wife. → Read More
Patients who took the medication retained a higher level of certain motor functions than those given a placebo, researchers say. → Read More
A new paper in Nature helps unravel why some conditions might manifest themselves more commonly, or intensely, in one sex over another. → Read More
A new study confirms what many oncologists have known, anecdotally, for years: that a chemotherapy drug can dramatically improve the odds of some patients. → Read More
"Some of my colleagues are nervous about working with Covid-19 patients, but a lot of people are just kind of happy ... to help out," the ICU nurse said. → Read More
To mark the highs and lows of 2019, STAT is continuing its annual tradition: the life-science year in review in limericks. → Read More
Companies like 23andMe and Ancestry.com have made it impossible for sperm banks to keep donors’ identities secret → Read More
STAT sat down with Dr. Richard Hodes, director of the NIH’s National Institute on Aging, at the Alzheimer’s Association International Conference. → Read More
Christian Angermayer, a German financier, is one of the driving forces behind the movement to turn psychoactive substances into drugs for mental illness. → Read More
Currently the private sector is largely unwilling to take on the financial risk of developing new antiotiics, even though they are desperately needed. → Read More
Researchers found that melanoma patients were 70 percent less likely to respond to cancer immunotherapy if they were also taking probiotic supplements. → Read More
Companies have little incentive to make a drug like BCG, which is remarkably effective at treating bladder cancer but hardly lucrative. → Read More
To mark the highs and lows of 2018, STAT is continuing its annual tradition: the life-science year in review in limericks. → Read More
A Florida-based drug maker now has the ability to charge a premium on a drug that has come free or dirt cheap for many patients for decades. → Read More
By quickly analyzing thousands — even millions — of cells, it’s now possible to visualize the specific cellular culprits for any given disease. → Read More
A massive genetic study touches on the question of whether it’s worthwhile, or even ethical, to study the genetics of sexual attraction in the first place. → Read More
Thanks to a remarkable effort on the part of Boston Children’s Hospital scientists, regulators, and the family of a girl, an experimental therapy was developed in record time. → Read More